Femasys Logo
Main Menu

Resources

Find the latest news about Femasys, including our media mentions, scientific publications, and more.

Kathy Lee-Sepsick on Wharton Business Daily

  • Wharton Business Daily

Femasys is committed to providing women with revolutionary healthcare products: CEO

  • AlphaStreet

Bloomberg Businessweek: Medical Tech for Women

  • Bloomberg

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

  • GlobeNewswire

FemaSeed Shows Positive Results for Infertility Treatment

  • Contemporary OB/GYN

FemaSeed: A Breakthrough Solution Proving Promise in Overcoming Infertility Challenges

  • CSIMarket
Load More

Femasys Creates Products and Procedures for the Fallopian Tubes

  • FemTech Focus Podcast

Advancements in Technologies Changing Reproductive Healthcare with Kathy Lee-Sepsick

  • Empowered Patient Podcast

Femasys Inc: Putting the Focus on Women’s Reproductive Health

  • Benchtop Bios

Femasys: Revolutionizing Female Reproduction (NASDAQ:FEMY)

  • Seeking Alpha

Anne Morrissey Joins Femasys as a New Board Member to Help Advance FEMASEED into Clinical Development

  • Femtech Insider

Women’s Health Company Femasys Files for $40M IPO

  • Femtech Insider

Femasys Targets Male Infertility with Updated Trial Design

  • BioWorld

Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

  • GlobeNewswire

Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

  • GlobeNewswire

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

  • GlobeNewswire

Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team

  • GlobeNewswire

Tech Companies Working On Contraception Face A New Landscape After Roe

  • Buzzfeed News
Load More

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

  • GlobeNewswire

Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

  • GlobeNewswire

Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch

  • GlobeNewswire

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

  • GlobeNewswire

FemCerv®: Well-designed technology that can minimize patient discomfort

  • MDedge

The Post-Roe Fertility Journey

  • SXSW
Load More

Kathy Lee-Sepsick on Wharton Business Daily

  • Wharton Business Daily

Femasys is committed to providing women with revolutionary healthcare products: CEO

  • AlphaStreet

Bloomberg Businessweek: Medical Tech for Women

  • Bloomberg

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

  • GlobeNewswire

FemaSeed Shows Positive Results for Infertility Treatment

  • Contemporary OB/GYN

FemaSeed: A Breakthrough Solution Proving Promise in Overcoming Infertility Challenges

  • CSIMarket
Load More

VIDEO: President and CEO, Kathy Lee-Sepsick speaks to connecting with the audience

  • YouTube

VIDEO: President and CEO, Kathy Lee-Sepsick at SLS

  • YouTube

VIDEO: Femasys KOL Event

  • YouTube

Media Kits

For additional information, please email media@femasys.com

Corporate Kit

Infertility Kit

Contraception Kit

Biopsy Kit

About Femasys
Investor Relations
Resources
Contact Us
Healthcare Professionals
Patients
Privacy Policy
Terms of Use
Patents
Accessibility
Copyright © 2024 Femasys Inc.
FemaSeed, FemBloc, FemCath, FemCerv, and FemVue are registered trademarks of Femasys Inc.
Main Menu